Alecensa (alectinib) — Medica
Non-Small Cell Lung Cancer – Adjuvant Therapy
Initial criteria
- age ≥ 18 years
- anaplastic lymphoma kinase (ALK)-positive disease
- used following tumor resection (tumors ≥ 4 cm or node positive)
- mutation detected by an approved test
Approval duration
2 years